Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | WDR5 | P61964 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCND3 | P30281 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 5/20 | 0.36 |
| ▸ | NEK7 | Q8TDX7 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | GPR6 | P46095 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10172682 | 0.94 | ERBB2 (0.47) | GPR119ERBB2CYP3A4CYP2C9WDR5 | |
| SCHEMBL10171903 | 0.93 | GPR119 (0.48) | GPR119ERBB2CYP3A4CYP2C9WDR5 | |
| SCHEMBL356433 | 0.92 | GPR119 (0.45) | GPR119ERBB2CYP3A4CYP2C9WDR5 | |
| SCHEMBL10172615 | 0.92 | GPR119 (0.46) | GPR119ERBB2CYP3A4CYP2C9WDR5 | |
| SCHEMBL10172612 | 0.92 | GPR119 (0.48) | GPR119ERBB2CYP3A4CYP2C9WDR5 | |
| SCHEMBL10172676 | 0.91 | GPR119 (0.45) | GPR119ERBB2CYP3A4CYP2C9WDR5 | |
| SCHEMBL356278 | 0.91 | GPR119 (0.46) | GPR119ERBB2CYP3A4CYP2C9WDR5 | |
| SCHEMBL10172604 | 0.91 | GPR119 (0.48) | GPR119ERBB2CYP3A4CYP2C9BRAF | |
| SCHEMBL10171818 | 0.89 | GPR119 (0.53) | GPR119ERBB2CYP3A4CYP2C9WDR5 | |
| SCHEMBL10171956 | 0.89 | GPR119 (0.44) | GPR119ERBB2CYP3A4CYP2C9WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| EP-2390254-A1 | NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-20110257678-A1 | VASCULAR EMBOLIC FILTER EXCHANGE DEVICES AND METHODS OF USE THEREOF | INCEPT LLC (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | GPR119, GPR139, HCAR1 | GPR119 1/4885ERBB2 451/4885CYP3A4 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.